Agile Therapeutics Interest Expense 2011-2026 | AGRX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Agile Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.42 M	3.13 M	3.91 M	3.11 M	-	1.12 M	1.92 M	2.45 M	2.08 M	1.57 M	1.51 M	140 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
3.91 M	140 K	2.03 M

Quarterly Interest Expense Agile Therapeutics

2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
185 K	185 K	-	341 K	372 K	402 K	-	1 M	823 K	872 K	-	999 K	993 K	922 K	-	905 K	902 K	398 K	-	268 K	320 K	368 K	-	268 K	320 K	368 K	-	459 K	504 K	546 K	-	784 K	548 K	548 K	-	552 K	548 K	426 K	-	392 K	403 K	378 K	-	378 K	378 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1 M	185 K	531 K

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Cumberland Pharmaceuticals CPIX	496 K	$ 6.29	7.07 %	$ 93.4 M	USA
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	501 K	-	-	$ 36.6 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
AcelRx Pharmaceuticals ACRX	134 K	-	7.5 %	$ 6.35 M	USA
DURECT Corporation DRRX	2.4 M	-	-	$ 50.1 M	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Cronos Group CRON	-241 K	$ 2.75	0.18 %	$ 1.05 B	Canada
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Harrow Health HROW	47 K	$ 33.59	1.79 %	$ 1.23 B	USA
Avadel Pharmaceuticals plc AVDL	13 M	-	-	$ 2.06 B	France
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
Pacira BioSciences PCRX	-373 K	$ 24.14	3.38 %	$ 1.12 B	USA
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
Bausch Health Companies BHC	-142 M	$ 5.43	-0.82 %	$ 2.01 B	Canada
Organogenesis Holdings ORGO	-5 K	$ 2.63	-1.32 %	$ 333 M	USA
Canopy Growth Corporation CGC	74.6 M	$ 1.05	1.1 %	$ 113 M	Canada
Solid Biosciences SLDB	824 K	$ 6.8	2.64 %	$ 595 M	USA
Sonoma Pharmaceuticals SNOA	-10 K	$ 1.08	-2.27 %	$ 1.34 M	USA
Jupiter Wellness JUPW	152 K	-	-	$ 33.6 M	USA
Tilray TLRY	46.6 M	$ 5.42	2.46 %	$ 3.35 B	Canada
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Evolus EOLS	-539 K	$ 6.2	1.72 %	$ 400 M	USA
Sundial Growers SNDL	81 K	$ 1.44	-0.68 %	$ 3.37 M	Canada
Emergent BioSolutions EBS	54.2 M	$ 9.06	7.22 %	$ 485 M	USA
Veru VERU	768 K	$ 2.3	-2.17 %	$ 33.7 M	USA
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Assertio Holdings ASRT	2.78 M	$ 23.45	0.04 %	$ 150 M	USA
ProPhase Labs PRPH	764 K	-	-	$ 5.07 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
cbdMD YCBD	34.3 K	$ 0.74	-2.6 %	$ 2.98 M	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 7.03	-0.21 %	$ 278 M	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	3.13 M	$ 0.7	-4.33 %	$ 35 M	USA
Viatris VTRS	471 M	$ 16.29	-2.19 %	$ 19 B	USA
Zomedica Corp. ZOM	-144 K	-	-0.21 %	$ 98 M	USA
Zynerba Pharmaceuticals ZYNE	27 K	-	-	$ 55.5 M	USA
Rockwell Medical RMTI	-623 K	$ 0.75	-5.4 %	$ 27 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
China Pharma Holdings CPHI	27.3 K	$ 0.76	0.05 %	$ 3.26 M	China
TherapeuticsMD TXMD	300 K	$ 2.1	-1.16 %	$ 24.3 M	USA